Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Open-label Trial to Evaluate the Efficacy, Safety and Tolerability of Switching From the Glucagon-like Peptide-1 Receptor Agonists to Maridebart Cafraglutide in Adult Participants With Obesity or Overweight

NCT07575399 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT07575399
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07575399 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Open-label Trial to Evaluate the Efficacy, Safety and Tolerability of Switching From the Glucagon-like Peptide-1 Receptor Agonists to Maridebart Cafraglutide in Adult Participants With Obesity or Overweight
Lead sponsor
Amgen
Phase
Phase 3
Overall status
Recruiting
Start date
May 11, 2026
Completion date
February 28, 2028
Enrollment
300 (estimated)
Sites
53

Conditions

As the registry lists them; a condition with its own page is linked.

obesity or overweight